Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors


Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors

Mont-Saint-Guibert, Belgium – January 9, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has appointed Mr. Daniel Wildman as an Independent Director to its Board of Directors*

Mr. Wildman is a 40-year veteran of the medical device industry. He is currently the Chairman of the Board of Progenerative Medical, Inc. and a Strategic Advisor to several medical device and pharmaceutical companies. He also serves as member of the Board of Directors of UroGen Pharma, Ltd.

Mr. Wildman spent most of his career with Johnson & Johnson (“J&J”), where he led the Digital Surgery Strategy Initiative, J&J’s DuPuy Synthes Spine franchise and J&J’s Ethicon Biosurgery division. Before J&J, Mr. Wildman spent ten years with Boston Scientific Corporation in a variety of sales, marketing, operations, and strategic planning roles.

Robert Taub, Chairman of the Board of Directors of Nyxoah, commented: “We are delighted to welcome Mr. Wildman to Nyxoah’s Board. His wealth of experience and knowledge in the medical device and pharmaceutical industries will be invaluable as Nyxoah expands its R&D, clinical and commercial strategies.”

Mr. Wildman added: “I am very impressed by the patient-centric design of Nyxoah’s Genio® hypoglossal nerve stimulation system and the benefits it can offer those suffering with obstructive sleep apnea. As a member of the Board, I look forward to working with Nyxoah’s leadership team to obtain approval and launch Genio® in the United States.”

* Wildman Ventures LLC, represented by Mr. Daniel Wildman, has been appointed as Director. The appointment is effective immediately, subject to confirmation by the Company’s shareholders at the next shareholders' meeting.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements 
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; future financial performance and market position; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
David DeMartino
Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313


Attachment

  • ENGLISH_Board Additions PR - Jan 2023 - FINAL


Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors

THỦ THUẬT HAY

Cách mở các tab vừa đóng trên iPhone hoặc iPad

Các trình duyệt trên điện thoại di động hiện đại cho phép bạn mở lại các tab vừa đóng, giống như các trình duyệt trên máy tính để bàn. Trong trình duyệt Safari của Apple dành cho iPhone và iPad, tính năng này ẩn, nhưng

Làm thế nào để iPhone đọc tên người gọi đến khi có cuộc gọi?

Bạn đang bận làm việc gì đó mà không thể cầm iPhone để xem cuộc gọi đến nhưng vẫn muốn biết người gọi là ai, cuộc gọi có quan trọng hay không để trả lời thì mẹo hay dưới đây mà TECHRUM giới thiệu sẽ giúp bạn giải quyết

Smarty Uninstaller: Công cụ hỗ trợ gỡ bỏ phần mềm đang miễn phí bản quyền chính chủ

Chắc hẳn bạn đã không còn xa lạ gì với công cụ hỗ trợ gỡ bỏ phần mềm Your Uninstaller! Tuy nhiên thay vì sử dụng một phiên bản 'bẻ khóa' và tiềm ẩn nhiều mối nguy hại cho thiết bị của mình, TCN xin chia sẻ cùng bạn đọc

Cách lịch sử tìm kiếm trên Google đã lưu trước đó trên mọi thiết bị

Giống như Facebook và Apple, Google đã giới thiệu chính sách bảo mật người dùng mới để tuân thủ luật bảo mật dữ liệu mới của GDPR sẽ có hiệu lực vào ngày 25 tháng 5. Quan trọng hơn, Google đã cải thiện việc kiểm soát

Hướng dẫn sạc và sử dụng Laptop đúng cách

Cách sử dụng Laptop của mỗi người khác nhau và thông thường các bạn đang có những suy nghĩ sai lêch về cách sử dụng. Bài viết dưới đây, dienmayxanh.com sẽ đưa ra một vài gợi ý giúp bạn sử dụng và sạc Laptop một cách

ĐÁNH GIÁ NHANH

Đánh giá Honda CBR650F 2018 - Mô-tô tầm trung gây sốt trên toàn thế giới

Xuất hiện lần đầu tiên trên thế giới vào năm 1991, CBR600F sau đó đã được thay thế bằng mẫu CBR600F2, huyền thoại này được đánh giá là một trong những chiếc xe máy tốt nhất mọi thời đại.

Đánh giá camera iPhone 13 Pro Max: Chụp ảnh, quay video đỉnh chóp xứng nhanh đệ nhất

iPhone 13 Pro Max là mẫu iPhone cao cấp nhất của nhà Táo hiện nay. Không chỉ sở hữu cấu hình siêu mạnh mẽ, màn hình 120Hz siêu mượt, iPhone 13 Pro Max còn được nâng cấp rất nhiều cho hệ thống camera. Bài đánh giá

Đánh giá nhanh Xiaomi Mi Max 3: Phù hợp vỡi những tiêu chí “ngon, bổ, rẻ”

Sau sự thành công vang dội của hai người đàn anh Mi Max và Mi Max 2, Xiaomi đã tiếp tục cho ra mắt Mi Max 3 với sự nâng cấp đáng kể về thiết kế màn hình viền mỏng, hiệu năng mạnh mẽ cùng chip Snapdragon 636, dung lượng